Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Effects of Maternal Anti-HIV Treatment on Infants Born to HIV-Infected Women

This study has been completed.
Information provided by:
AIDS Clinical Trials Group Identifier:
First received: January 6, 2005
Last updated: September 15, 2010
Last verified: September 2010

January 6, 2005
September 15, 2010
June 2006
May 2010   (final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT00100867 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Effects of Maternal Anti-HIV Treatment on Infants Born to HIV-Infected Women
Assessment of Safety and Toxicity Among Infants Born to HIV-1-Infected Women Enrolled in Antiretroviral Treatment Protocols in Diverse Areas of the World

In clinical trials being conducted throughout the world, pregnant HIV-infected women are given anti-HIV drugs before, during, and after they give birth to prevent mother-to-child transmission of HIV. However, the effects of this anti-HIV treatment on infants is unknown. The purpose of this study is to determine the safety, toxicity, and potential side effects of maternal anti-HIV treatment on infants born to these HIV-infected women.

Study hypothesis: Specific combination antiretroviral regimens used in clinical trials in diverse areas of the world are safe and well tolerated during pregnancy and breastfeeding periods, and are not associated with adverse side effects to the fetus, neonate, and/or breastfeeding infant. These regimens are associated with reduction of mother-to-child HIV transmission.

Many HIV-infected women outside the United States enroll in clinical trials that provide them antiretroviral therapy (ART) to prevent mother-to-child transmission of HIV. However, data are limited on the safety, toxicity, and adverse effects that maternal ART may have on infants born to HIV-infected women. This study will monitor the adverse effects and potential benefits of maternal ART on these infants.

No antiretrovirals will be given in this study. This study will last 18 months. Infants will be enrolled in the study within 48 hours of birth. There will be 6 study visits starting at study entry and every 6 weeks thereafter. Infants will undergo blood and urine collection, and medical history assessments will occur at every visit. Mothers will also be evaluated at these visits.

Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Retention:   Samples With DNA

Blood and urine collection

Non-Probability Sample

Infants born to HIV-infected women

HIV Infections
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
May 2010
May 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Infant born to HIV-1 infected mother enrolled in NIH-sponsored, international antiretroviral treatment trial AND who has had either in utero or postpartum antiretroviral exposure
  • Parent or guardian willing to provide informed consent

Exclusion Criteria:

  • Infant with no exposure to antiretrovirals OR who received only intrapartum antiretroviral exposure
Not Provided
Contact information is only displayed when the study is recruiting subjects
Botswana,   Brazil,   India,   Malawi,   Peru,   South Africa,   Thailand,   Zimbabwe
ACTG A5190-P1054, 1U01AI068636, ACTG A5190, PACTG P1054
Not Provided
Daniel R. Kuritzkes, M.D., Social & Scientific Systems, Inc.
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)
Study Chair: Karin Nielsen, MD, MPH University of California, Los Angeles
Study Chair: Judith S. Currier, MD, MSc Center for AIDS Research and Education, University of California, Los Angeles
AIDS Clinical Trials Group
September 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP